» Articles » PMID: 18552171

Do Patients with Low Volume Prostate Cancer Have Prostate Specific Antigen Recurrence Following Radical Prostatectomy?

Overview
Journal J Clin Pathol
Specialty Pathology
Date 2008 Jun 17
PMID 18552171
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The objective of this study was to determine the incidence of prostate specific antigen (PSA) relapse in patients with low volume prostate cancer following radical prostatectomy.

Methods: Between 1993 and 2001, 50 of 717 patients had total tumour volumes of less than 0.5 cm3 following radical prostatectomy. Biochemical recurrence was defined as two consecutive values of serum PSA levels of 0.2 ng/ml or greater.

Results: Median follow-up of the 50 patients was 58 months. In five of the 50 patients (10%), PSA recurrence was observed. All of these five cases had Gleason score of 3+3 (well and/or moderately differentiated), organ confined and surgical margin negative tumours. In three of the five cases, capsular incision resulted in benign glands extending into the surgical margin.

Conclusions: Five of 50 cases had PSA failure. In three of the five patients, benign glands located in the margin could explain the "PSA recurrence". However, in the other two patients, none of the pathological parameters correlated with measurable PSA levels. The explanation for their PSA failure is unclear.

Citing Articles

Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer.

Baba H, Sakamoto S, Zhao X, Yamada Y, Rii J, Fujimoto A Cancers (Basel). 2022; 14(23).

PMID: 36497304 PMC: 9740872. DOI: 10.3390/cancers14235823.


Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies.

McCormick B, Mahmoud A, Williams S, Davis J Indian J Urol. 2019; 35(1):6-17.

PMID: 30692719 PMC: 6334583. DOI: 10.4103/iju.IJU_355_18.


Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?.

Kataria S, Koneru H, Guleria S, Danner M, Ayoob M, Yung T Front Oncol. 2017; 7:157.

PMID: 28791252 PMC: 5522851. DOI: 10.3389/fonc.2017.00157.


TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.

Albadine R, Latour M, Toubaji A, Haffner M, Isaacs W, Platz E Mod Pathol. 2009; 22(11):1415-22.

PMID: 19734849 PMC: 3354529. DOI: 10.1038/modpathol.2009.121.